Tredje AP fonden Has $9.03 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Tredje AP fonden lowered its stake in Agilent Technologies, Inc. (NYSE:A) by 10.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 69,621 shares of the medical research company’s stock after selling 8,329 shares during the quarter. Tredje AP fonden’s holdings in Agilent Technologies were worth $9,025,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in A. Livelsberger Financial Advisory bought a new position in shares of Agilent Technologies during the fourth quarter worth $26,000. Crewe Advisors LLC lifted its holdings in Agilent Technologies by 114.8% during the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Ridgewood Investments LLC acquired a new position in Agilent Technologies in the second quarter valued at about $29,000. Rise Advisors LLC increased its holdings in shares of Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after acquiring an additional 190 shares in the last quarter. Finally, YHB Investment Advisors Inc. acquired a new stake in shares of Agilent Technologies during the first quarter worth about $34,000. 87.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Jefferies Financial Group reissued a “hold” rating and set a $135.00 target price (down from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Citigroup raised their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. UBS Group upped their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $151.00 price target on shares of Agilent Technologies in a research note on Monday, August 26th. Finally, Wells Fargo & Company assumed coverage on Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price objective for the company. One analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $141.60.

Agilent Technologies Stock Up 0.5 %

Agilent Technologies stock opened at $139.01 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. The company’s 50-day moving average is $137.50 and its 200-day moving average is $139.25. The firm has a market capitalization of $40.56 billion, a PE ratio of 32.86, a P/E/G ratio of 6.43 and a beta of 1.05. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the previous year, the business earned $1.43 earnings per share. The business’s revenue was down 5.6% compared to the same quarter last year. Sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.